Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia

This trial is testing a new type of immune cell therapy called CAR-T cells for people with acute myeloid leukemia (AML) — a blood cancer — that has come back or stopped responding to treatment. The therapy involves engineering a patient's own immune cells to target cancer cells that carry a protein called FLT3. **You may be eligible if...** - You are between 18 and 70 years old - You have AML that has not gone into remission after treatment, or has relapsed - Your cancer cells have a FLT3 mutation or high FLT3 protein expression - Your heart, liver, kidneys, and lungs are functioning adequately - You are in reasonably good health (able to care for yourself) **You may NOT be eligible if...** - You have acute promyelocytic leukemia (a specific AML subtype called APL/M3) - You have previously received CAR-T cell therapy - You have active hepatitis B, hepatitis C, HIV, or syphilis - You have a history of serious heart problems - You had a blood clot in the past 3 months - You are pregnant, breastfeeding, or planning pregnancy within a year Talk to your doctor to see if this trial is right for you.